吡非尼酮联合尼达尼布治疗小鼠肺纤维化的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect and method of Pirfenidone combined with Nintedanib treating pulmonary fibrosis in mice. Methods All of 90 male Kunming mice aged 6-8 weeks were selected, After 1 week of adaptive feeding, and among them, 10 mice were randomly selected as control group, and the other 80 mice were treated with Bleomycin to establish pulmonary fibrosis model. The pulmonary function of the mice was measured by Buxco animal pulmonary function analysis system. The Penh value increased to more than 1.5, and the model was established successfully. 40 model mice were selected randomly from successful mice modeling and randomly divided into control group (0.1 ml normal saline, 3 times a day), Pirfenidone group (400 mg/kg, 3 times a day), Nintedanib group (150 mg/kg,2 times a day), Pirfenidone (400 mg/kg, 3 times a day) combined with Nintedanib group (150 mg/kg, 2 times a day).The mice were gavaged for 3 weeks. Penh value was measured using the above-mentioned method. Then the mice were sacrificed after anaesthetized. The alveolar lavage fluid was collected and centrifuged, then the cells were obtained. After Swiss-Giemsa staining, the white cells in alveolar lavage fluid of mice were counted under inverted microscope.Results A total of 80 mice were modeled and 50 mice (62.5%) were successfully modeled. After treatment, the Penh value in Pirfenidone group combined with Nintedanib group were lower than those in Pirfenidone group (P＜0.05),Nintedanib group (P＜0.05) and control group (P＜0.01). The leukocyte of Pirfenidone combined with Nintedanib group was fewer than that of Pirfenidone group (P＜0.05), Nintedanib group (P＜0.05) and control group (P＜0.01). Conclusion The therapeutic effect of Pirfenidone combined with Nintedanib is the best, which lays a foundation for the clinical use of this method in the treatment of pulmonary fibrosis.

Key words： Pirfenidone Nintedanib Combined treatment Idiopathic pulmonary ifbrosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xue
	LI Qiao-ling
	GAO Yun-yun
	DENG Wen

Cite this article:

WANG Xue,LI Qiao-ling,GAO Yun-yun, et al. The effect of Pirfenidone combined with Nintedanib treating pulmonary fibrosis in mice[J]. 中国当代医药, 2019, 26(9): 38-40.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I9/38

[1]	牛晓娟.阿奇霉素对博来霉素致大鼠肺纤维化的干预作用及机制[D].石家庄：河北医科大学，2012：8.
[2]	郭敬文，张振玲，邵华，等.肺纤维化药物治疗机制研究进展[J].中国职业医学，2017，44（5）：633-637.
[3]	赵玉珂，赵铭山，秦静，等.吡非尼酮对特发性肺纤维化治疗的研究进展[J].当代医学，2013，19（9）：12-13.
[4]	陈钰清，闫永吉，仇美华，等.吡非尼酮治疗肺纤维化的疗效与安全性meta 分析[J].临床药物治疗杂志，2016，14（4）：13-22.
[5]	邵明香，王维亭，赵专友，等.抗肺纤维化新药吡非尼酮[J].现代药物与临床，2013，28（3）：409-414.
[6]	蔡颖.尼达尼布在呼吸系统疾病治疗中的临床评价[J].世界临床药物，2013，34（10）：631-633.
[7]	邢洁，张洁.治疗特发性肺纤维化新药尼达尼布的研究进展[J].中国药房，2015，26（29）：4174-4176.
[8]	刘传梅，蔡后荣.特发性肺纤维化药物治疗进展[J].临床药物治疗杂志，2015，13（3）：1-4.
[9]	陈卓.特发性肺纤维化病机制及药物治疗进展[D].重庆：重庆医科大学，2016：6-16.
[10]	魏燕华，刘桂桃.肺纤维化的治疗进展[J].临床肺科杂志，2014，19（2）：336-339.
[11]	杜文静，董竞成.特发性肺纤维化的治疗研究进展[A]//第三届民族传统医学与现代医学国际学术大会暨第十三次全国中西医结合防治呼吸系统疾病学术研讨会论文集[C].2014：319-322.
[12]	马战平，李猛，黄刚，等.特发性肺纤维化的中医药研究进展[A]//全国第十九次中医肺系病学术交流会暨2015年浙江省中医药学会呼吸病分会学术年会论文集[C].2015：1-7.
[13]	唐连涛.特发性肺纤维化治疗进展[J].医学综述，2012，18（9）：1309-1311.
[14]	班健.特发性肺纤维化的治疗进展[J].临床肺科杂志，2011，16（9）：1432-1434.
[15]	奚菊美.基于静电喷雾技术的尼达尼布纳米增溶与缓释体系的构建及体内外评价[D].镇江：江苏大学，2016：1-2.
[16]	赵永强，楚海燕，滕礼，等.博莱霉素诱导肺纤维化小鼠模型的建立及特征[J].疑难病杂志，2013，12（9）：705-708.
[17]	陈孟毅.小鼠博来霉素多次染毒肺纤维化模型建立及ABT263 治疗作用观察[D].北京：北京协和医学院，2017：1-6.
[18]	崔红帅.阿奇霉素对博来霉素致小鼠肺纤维化中ILK 及β-catenin 蛋白表达的影响[D].石家庄：河北医科大学.2017：1-8.